More than 50 years on from the discovery of vancomycin, there is still huge demand for novel glycopeptides antibiotics. Vancomycin’s clinical use was initially limited due to its side effects but the rise in the number of methicillin-resistant bacteria forced it back to the forefront of research. Now vancomycin-resistant bacteria are on the increase and so scientists have been trying to make new glycopeptides antibiotics in a variety of ways.
